Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

Part of paid clinical trials in Los Angeles, California.

Sponsor
Institut Paoli-Calmettes
Study ID
NCT03961776
Status
Recruiting
Apply to this trial

Conditions

  • Rectal Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MRI-guided radiotherapy by on-board DWI sequences — DEVICE
    The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes.

Study Details

feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.

Key Dates

Start date
Jun 8, 2020
Status verified
May 2021
Primary completion
May 31, 2022
Completion
May 31, 2027

Study Design

Enrollment
39 participants (estimated)

Arms

  • Arm: non-metastatic rectal adenocarcinoma nRCT indicated
    Patients with histologically confirmed non-metastatic rectal adenocarcinoma and for whom treatment with nRCT has been indicated.

Primary Outcome Measure

Predictive value of Apparent Diffusion Coefficient measured using MRgRT system [ Time Frame: At surgery (5 to 10 weeks after completion of chemoradiation) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California Los Angeles (UCLA)Los AngelesCalifornia90095-1406
Percy LEE, MD
Percy LEE (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By research site
University of California Los Angeles (UCLA)· Los Angeles, CA

Related Studies